Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Serafina Guadagnuolo"'
Autor:
Serena De Matteis, Michele Dicataldo, Beatrice Casadei, Gianluca Storci, Noemi Laprovitera, Mario Arpinati, Enrico Maffini, Pietro Cortelli, Maria Guarino, Francesca Vaglio, Maria Naddeo, Barbara Sinigaglia, Luca Zazzeroni, Serafina Guadagnuolo, Enrica Tomassini, Salvatore Nicola Bertuccio, Daria Messelodi, Manuela Ferracin, Massimiliano Bonafè, Pier Luigi Zinzani, Francesca Bonifazi
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
BackgroundInfusion of second generation autologous CD19-targeted chimeric antigen receptor (CAR) T cells in patients with R/R relapsed/refractory B-cell lymphoma (BCL) is affected by inflammatory complications, such as Immune Effector Cell-Associated
Externí odkaz:
https://doaj.org/article/f9964366181e4ab280f57b54a8321f14
Autor:
Arianna Marini, Omar Rossi, Maria Grazia Aruta, Francesca Micoli, Simona Rondini, Serafina Guadagnuolo, Isabel Delany, Ian R Henderson, Adam F Cunningham, Allan Saul, Calman A MacLennan, Oliver Koeberling
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0181508 (2017)
Factor H-binding protein (fHbp) is an important meningococcal vaccine antigen. Native outer membrane vesicles with over-expressed fHbp (NOMV OE fHbp) have been shown to induce antibodies with broader functional activity than recombinant fHbp (rfHbp).
Externí odkaz:
https://doaj.org/article/92829ddf9edc4fb2ae8c5a53e36b46b5
Autor:
Luca Fagnocchi, Silvia Bottini, Giacomo Golfieri, Laura Fantappiè, Francesca Ferlicca, Ana Antunes, Serafina Guadagnuolo, Elena Del Tordello, Emilio Siena, Davide Serruto, Vincenzo Scarlato, Alessandro Muzzi, Isabel Delany
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0126325 (2015)
Most bacterial small RNAs (sRNAs) are post-transcriptional regulators involved in adaptive responses, controlling gene expression by modulating translation or stability of their target mRNAs often in concert with the RNA chaperone Hfq. Neisseria meni
Externí odkaz:
https://doaj.org/article/697eef69f2ae43aea7bc57cd66fd7549
Autor:
Serafina Guadagnuolo, Michele Bartoletti, Alessandro Broccoli, Ginevra Lolli, Elena Sabattini, Vittorio Stefoni, Michele Dicataldo, Lisa Argnani, Beatrice Casadei, Maria Guarino, Alice Morigi, Stefano Fanti, Elisabetta Pierucci, Laura Nanni, Pier Luigi Zinzani, Francesca Bonifazi, Cinzia Pellegrini, Luca Spinardi
Publikováno v:
Cancers
Volume 13
Issue 19
Cancers, Vol 13, Iss 4789, p 4789 (2021)
Volume 13
Issue 19
Cancers, Vol 13, Iss 4789, p 4789 (2021)
Simple Summary CAR T-cell therapies have undoubtedly revolutionized the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. These therapies represent a valuable new treatment option, yielding impressive complete remission rates and improvin
Autor:
P. L. Zinzani, Lisa Argnani, Silvia Turroni, Serafina Guadagnuolo, Beatrice Casadei, Patrizia Brigidi, Monica Barone
Publikováno v:
Hematological Oncology. 39
Autor:
Serafina Guadagnuolo, M. Santoro, Beatrice Casadei, Andrea Paccagnella, A. Farolfi, Lidia Strigari, P. L. Zinzani, Stefano Fanti, G. Paolani, C. Malizia, Francesca Bonifazi, S. Strolin, Lisa Argnani, G. Della Gala
Publikováno v:
Hematological Oncology. 39
Autor:
Patrizia Brigidi, Silvia Turroni, Beatrice Casadei, Monica Barone, Serafina Guadagnuolo, Pier Luigi Zinzani, Lisa Argnani
Publikováno v:
Blood. 138:2957-2957
Single-agent monoclonal antibodies targeting the immune checkpoint PD1 (programmed death 1) are an efficient and safe therapeutic option in patients with relapsed/refractory B-cell lymphoma. However, many patients progress or lose response to anti-PD
Autor:
Javier Delgado Serrano, Paolo Corradini, Alejandro Martin Garcia-Sancho, Pier Luigi Zinzani, Lina Camacho, Juan Reguera, Serafina Guadagnuolo, Mariana Bastos-Oreiro, Pere Barba, Gloria Iacoboni, Kai Rejeski, Mi Kwon, Christian Schmidt, Lucía López Corral, Cecilia Carpio, Marion Subklewe, Annalisa Chiappella
Publikováno v:
Blood. 138:2827-2827
Introduction Brexucabtagene autoleucel (brexu-cel) is a second generation, CD19-targeted Chimeric Antigen Receptor (CAR) T-cell therapy approved for relapsed or refractory (R/R) mantle cell lymphoma (MCL). The pivotal phase 2 trial ZUMA-2 enrolled 74
Autor:
Isabel Delany, Adam F. Cunningham, Omar Rossi, Ian R. Henderson, Maria Grazia Aruta, Simona Rondini, Calman A. MacLennan, Oliver Koeberling, Serafina Guadagnuolo, Arianna Marini, Allan Saul, Francesca Micoli
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0181508 (2017)
PLoS ONE
PLoS ONE
Factor H-binding protein (fHbp) is an important meningococcal vaccine antigen. Native outer membrane vesicles with over-expressed fHbp (NOMV OE fHbp) have been shown to induce antibodies with broader functional activity than recombinant fHbp (rfHbp).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f952a543cef7ce33e68c4bf6e54c211b
https://doi.org/10.1371/journal.pone.0181508
https://doi.org/10.1371/journal.pone.0181508